Helix BioPharma Corp (HBP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Helix BioPharma Corp (HBP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3292
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. It develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company’s proprietary broad anti-cancer therapeutic platform has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company’s proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Aurora, Ontario, Canada.

Helix BioPharma Corp (HBP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Helix BioPharma Plans Partnership For L-DOS47 11
Helix Biopharma Enters into Agreement with ProMab Biotechnologies 12
Helix BioPharma and Moffitt Cancer Center Enter into Agreement 13
Licensing Agreements 14
Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 14
Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 15
Helix Polska Enters into Licensing Agreement with Helix BioPharma 16
Equity Offering 17
Helix BioPharma Raises USD0.8 Million in Private Placement of Units 17
Helix BioPharma Raises USD0.5 Million in Private Placement of Units 18
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 19
Helix BioPharma Raises USD3 Million in Private Placement of Units 20
Helix BioPharma Raises USD1 Million in Private Placement of Units 21
Helix BioPharma Raises USD2.3 Million in Private Placement of Units 22
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 23
Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 24
Helix BioPharma Raises USD1 Million in Private Placement of Units 25
Helix BioPharma Raises USD1.4 Million in Private Placement of Units 26
Helix BioPharma Raises USD3.58 Million in Private Placement of Units 27
Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 28
Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 29
Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 30
Helix BioPharma Completes Private Placement Of Common Stock And Warrants 31
Asset Transactions 32
Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For US$8.6 Million 32
Helix BioPharma Corp – Key Competitors 33
Helix BioPharma Corp – Key Employees 34
Helix BioPharma Corp – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Jun 12, 2018: Helix BioPharma Reports Fiscal Third Quarter 2018 Financial Results 36
Mar 20, 2018: Helix BioPharma Announces Fiscal Second Quarter 2018 Results 38
Dec 13, 2017: Helix BioPharma Announces Fiscal First Quarter 2018 Results 40
Oct 27, 2017: Helix BioPharma Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update 41
Jun 13, 2017: Helix BioPharma Announces Fiscal Third Quarter 2017 Results 43
Mar 17, 2017: Helix BioPharma Announces Fiscal Second Quarter 2017 Results 45
Corporate Communications 46
Mar 22, 2018: Helix BioPharma Welcomes Drs. Daniel Von Hoff, Kazimierz Roszkowski-Sliz and Robert Gillies to Its Scientific and Strategic Advisory Board 46
Dec 01, 2017: Helix BioPharma Announces Management Change 47
Jul 17, 2017: Helix BioPharma Director Resigns 48
Mar 07, 2017: Helix BioPharma Announces Strategic Management Changes 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Helix BioPharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Helix BioPharma Plans Partnership For L-DOS47 11
Helix Biopharma Enters into Agreement with ProMab Biotechnologies 12
Helix BioPharma and Moffitt Cancer Center Enter into Agreement 13
Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 14
Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 15
Helix Polska Enters into Licensing Agreement with Helix BioPharma 16
Helix BioPharma Raises USD0.8 Million in Private Placement of Units 17
Helix BioPharma Raises USD0.5 Million in Private Placement of Units 18
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 19
Helix BioPharma Raises USD3 Million in Private Placement of Units 20
Helix BioPharma Raises USD1 Million in Private Placement of Units 21
Helix BioPharma Raises USD2.3 Million in Private Placement of Units 22
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 23
Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 24
Helix BioPharma Raises USD1 Million in Private Placement of Units 25
Helix BioPharma Raises USD1.4 Million in Private Placement of Units 26
Helix BioPharma Raises USD3.58 Million in Private Placement of Units 27
Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 28
Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 29
Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 30
Helix BioPharma Completes Private Placement Of Common Stock And Warrants 31
Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For US$8.6 Million 32
Helix BioPharma Corp, Key Competitors 33
Helix BioPharma Corp, Key Employees 34
Helix BioPharma Corp, Subsidiaries 35

List of Figures
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Helix BioPharma Corp (HBP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Builders FirstSource Inc:戦略・SWOT・企業財務分析
    Builders FirstSource Inc - Strategy, SWOT and Corporate Finance Report Summary Builders FirstSource Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Akebia Therapeutics Inc (AKBA):製薬・医療:M&Aディール及び事業提携情報
    Summary Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF …
  • Himatsingka Seide Ltd:企業の戦略・SWOT・財務分析
    Himatsingka Seide Ltd - Strategy, SWOT and Corporate Finance Report Summary Himatsingka Seide Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Strad Energy Services Ltd (SDY):石油・ガス:M&Aディール及び事業提携情報
    Summary Strad Energy Services Ltd (Strad Energy) is a diversified company. The company offers services such as equipment rental, mat mobilization and demobilization, mobile mat washing and servicing, and drill cuttings management and invert recovery services. It rents various equipment including tan …
  • Vitasoy International Holdings Limited (345):企業の財務・戦略的SWOT分析
    Vitasoy International Holdings Limited (345) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Emcure Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Emcure Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Web.com Group, Inc.:企業の戦略的SWOT分析
    Web.com Group, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • GE Energy:戦略・SWOT・企業財務分析
    GE Energy - Strategy, SWOT and Corporate Finance Report Summary GE Energy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Hill-Rom Holdings Inc (HRC)-医療機器分野:企業M&A・提携分析
    Summary Hill-Rom Holdings Inc (Hill-Rom) is a medical technology company that offers patient support systems, surgical solutions and other front line care products. The company’s major products and services include patient care systems; safe mobility and handling solutions; non-invasive therapeutic …
  • Wuhan Kaidi Electric Power Co Ltd (000939):電力:M&Aディール及び事業提携情報
    Summary Wuhan Kaidi Electric Power Co Ltd (Wuhan Kaidi) is a renewable energy company that offers power supply and new energies technology and services. The company produces biomass energy from forestry and agricultural residues. Its services include technical research and development, investment an …
  • Hookipa Biotech AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Hookipa Biotech AG (Hookipa) is a biotechnology company that develops vaccines and next-generation immunotherapeutics for the prevention and treatment of cancer and infectious diseases. The company's lead product candidate include HB101 vaxwave, a vaccine under development for immunization a …
  • Quantum Utility Generation LLC:電力:M&Aディール及び事業提携情報
    Summary Quantum Utility Generation LLC (QUG) is an electric utility that acquires, develops, operates and optimizes power generation assets in the Americas. The utility generates electricity from various sources such as wind, coal and natural gas-based power generation plants. It also produces elect …
  • Sanofi (SAN):医療機器:M&Aディール及び事業提携情報
    Summary Sanofi is a healthcare company that researches, develops, manufactures and markets a wide range of medicines and vaccines. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protect …
  • Amgen, Inc.:企業の戦略・SWOT・財務情報
    Amgen, Inc. - Strategy, SWOT and Corporate Finance Report Summary Amgen, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Grupo Bimbo S.A. de C.V.:企業の戦略・SWOT・財務情報
    Grupo Bimbo S.A. de C.V. - Strategy, SWOT and Corporate Finance Report Summary Grupo Bimbo S.A. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Konica Minolta Medical Imaging USA Inc:医療機器:M&Aディール及び事業提携情報
    Summary Konica Minolta Medical Imaging USA Inc (KMMI), a subsidiary of Konica Minolta Inc is a medical device company that manufactures and distributes digital and traditional imaging products. The company provides comprehensive imaging solutions including, digital radiography, ultrasound, healthcar …
  • Covanta Holding Corp (CVA):企業の財務・戦略的SWOT分析
    Covanta Holding Corp (CVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Lamprell Plc (LAM):企業の財務・戦略的SWOT分析
    Lamprell Plc (LAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Catholic Health Initiatives:企業の戦略・SWOT・財務分析
    Catholic Health Initiatives - Strategy, SWOT and Corporate Finance Report Summary Catholic Health Initiatives - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Securitas AB:企業の戦略・SWOT・財務分析
    Securitas AB - Strategy, SWOT and Corporate Finance Report Summary Securitas AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆